Generic Topicort Availability
Topicort is a brand name of desoximetasone topical, approved by the FDA in the following formulation(s):
TOPICORT (desoximetasone - ointment; topical)
-
Manufacturer: TARO PHARMS NORTH
Approval date: January 17, 1985
Strength(s): 0.05% [RLD]
TOPICORT (desoximetasone - spray; topical)
Has a generic version of Topicort been approved?
No. There is currently no therapeutically equivalent version of Topicort available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Topicort. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with Topicort.
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- April 11, 2016 - NEW DOSAGE FORM
See also...
- Topicort cream Consumer Information (Wolters Kluwer)
- Topicort gel Consumer Information (Wolters Kluwer)
- Topicort Consumer Information (Cerner Multum)
- Topicort Advanced Consumer Information (Micromedex)
- Topicort Mild Advanced Consumer Information (Micromedex)
- Topicort AHFS DI Monographs (ASHP)
- Desoximetasone cream Consumer Information (Wolters Kluwer)
- Desoximetasone gel Consumer Information (Wolters Kluwer)
- Desoximetasone topical Consumer Information (Cerner Multum)
- Desoxi Advanced Consumer Information (Micromedex)
- Taro-Desoximetasone Advanced Consumer Information (Micromedex)
- Desoximetasone Topical application Advanced Consumer Information (Micromedex)
- Desoximetasone AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
